HomeCompareBRIBF vs SBUX

BRIBF vs SBUX: Dividend Comparison 2026

BRIBF yields 1062.70% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.83M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BRIBF vs SBUX

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRIBF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,818,970.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + SBUX for your $10,000?

BRIBF: 50%SBUX: 50%
100% SBUX50/50100% BRIBF
Portfolio after 10yr
$16042232.08M
Annual income
$13,536,504,082,295.66/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
SBUX buys
0
No recent congressional trades found for BRIBF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFSBUX
Forward yield1062.70%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$32084464.00M$167.0K
Annual income after 10y$27,073,008,093,454.87$71,136.45
Total dividends collected$31704729.30M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: BRIBF vs SBUX ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$116,970$106,269.93$11,121$420.68+$105.8KBRIBF
2$1,286,876$1,161,718.25$12,548$648.40+$1.27MBRIBF
3$13,321,776$11,944,818.28$14,440$1,013.98+$13.31MBRIBF
4$129,817,926$115,563,625.92$17,068$1,617.30+$129.80MBRIBF
5$1,191,375,681$1,052,470,500.56$20,912$2,649.52+$1191.35MBRIBF
6$10,301,704,979$9,026,933,000.21$26,875$4,499.29+$10301.68MBRIBF
7$83,971,400,363$72,948,576,035.34$36,771$8,014.12+$83971.36MBRIBF
8$645,568,504,677$555,719,106,288.88$54,542$15,197.11+$645568.45MBRIBF
9$4,683,603,649,023$3,992,845,349,018.69$89,602$31,242.49+$4683603.56MBRIBF
10$32,084,463,997,910$27,073,008,093,454.87$167,011$71,136.45+$32084463.83MBRIBF

BRIBF vs SBUX: Complete Analysis 2026

BRIBFStock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BRIBF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.